A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
Merck and Moderna's mRNA cancer vaccine, an expected nominee to lead the FDA, and more biotech news from The Readout ...
The American Cancer Society had an optics problem: its annual Wine and Spirits Industry's Gala. It decided to do something ...
Brain organoids kept alive more than five years continued to develop and mature, and showed molecular and genetic signatures ...
President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next ...
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful ...
At Epic's annual meeting, the prevailing question behind closed doors is “What the heck is going on with Epic?” ...
Morens said he had agreed to work to avoid public disclosures and to use his influence to advance a company's interests.
Experts question technical improvements Huidagene tried when using a Duchenne muscular dystrophy treatment strategy largely ...
The suit, brought by a nonprofit that advocates for plant-based diets, claims HHS and the USDA used a “secret panel” of ...
Financial incentives – health care makes up nearly one-fifth of the American economy – have driven every major AI company ...
Seven years after the nonprofit health system sold stakes in its in-house billing and collections company to private equity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results